Alfredo Torres, MD
Psychiatry · Monroe, LANPI 1033178975
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,059 of the $14,776 with a category attached, or 88.4%. It is spread thinly across 27 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,978, 2.4 times the $1,647 reported in 2019. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 628 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$3K
- Acadia Pharmaceuticals Inc$2K
- Beone Medicines USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$991
- Alkermes, Inc.$748
- plus $5K from 21 others
Across 44 payments — averaging $3388.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$70K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$59K
- Boehringer Ingelheim$20K
What the payments were for
- Consulting fees$1,65011%
- Food & beverage$13,05988%
- Education$670%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 88 | $2,800 |
| Acadia Pharmaceuticals Inc | 120 | $2,232 |
| Beone Medicines USA, Inc. | 1 | $1,650 |
| Otsuka America Pharmaceutical, Inc. | 49 | $1,321 |
| Teva Pharmaceuticals USA, Inc. | 56 | $991 |
| Alkermes, Inc. | 47 | $748 |
| Lundbeck LLC | 38 | $710 |
| AbbVie(2 entities) | 55 | $692 |
| Vanda Pharmaceuticals Inc. | 21 | $533 |
| Sunovion Pharmaceuticals Inc. | 27 | $491 |
| Johnson & Johnson | 20 | $391 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $339 |
| Axsome Therapeutics, Inc. | 10 | $325 |
| Avanir Pharmaceuticals, Inc. | 19 | $281 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $274 |
| E.r. Squibb & Sons, L.L.C. | 16 | $255 |
| Eisai Inc. | 6 | $212 |
| Livanova USA, Inc. | 2 | $135 |
| Idorsia Pharmaceuticals US Inc | 6 | $102 |
| Indivior Inc. | 5 | $101 |
| Merck | 4 | $59 |
| Alpha Cognition USA, Inc. | 2 | $39 |
| Shire North American Group Inc | 2 | $31 |
| Almatica Pharma LLC | 1 | $24 |
| Bioxcel Therapeutics, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,776 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 94 | $674,581 |
| RexultiBrexpiprazole | 164 | $259,110 |
| NuplazidPimavanserin Tartrate | 20 | $102,157 |
| TrintellixVortioxetine Hydrobromide | 94 | $51,285 |
| Invega SustennaPaliperidone Palmitate | 12 | $36,824 |
| Abilify MaintenaAripiprazole | 12 | $34,016 |
| Risperdal ConstaRisperidone Microspheres | 22 | $25,427 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $17,510 |
| VraylarCariprazine Hcl | 11 | $16,195 |
| Memantine Hcl | 428 | $9,269 |
| Doxepin Hcl | 48 | $8,824 |
| BelsomraSuvorexant | 19 | $7,496 |
| Aripiprazole | 191 | $4,786 |
| Quetiapine Fumarate | 337 | $4,673 |
| Clozapine | 36 | $4,447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,800 | $674,58194 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,321 | $293,126176 claims |
| Acadia Pharmaceuticals IncNuplazid | $2,232 | $102,15720 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $391 | $62,25134 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $339 | $51,28594 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $281 | $17,51021 claims |
| AbbVieVraylar | $692 | $16,19511 claims |
| MerckBelsomra | $59 | $7,49619 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $991 | $3,58361 claims |
| Almatica Pharma LLCSertraline Hcl | $24 | $1,144199 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Monroe
- Aruna GullapalliMonroe$10K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Roger BrownMandeville$216K
- Abdul KhanBaton Rouge$156K
- William ColombMandeville$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.